The anti-emetic, Cerenia (maropitant citrate), has gained licenses for use in puppies from as young as eight weeks of age and in cats from 16 weeks of age in the prevention and treatment of vomiting and reduction of nausea.
Cerenia is an NK-1 receptor antagonist which Pfizer says is effective against both peripheral and central emetic stimuli by acting on the final common pathway for emesis. It is, according to the company, the only NK-1 receptor antagonist licensed for dogs and cats.
Pfizer adds that in addition to the use for general emesis in puppies, Cerenia can also be used for chemotherapy-induced nausea in dogs. Studies in human oncology show that some patients receiving chemotherapy consider nausea to be more distressing than vomiting1. and the use of NK-1 receptor antagonists has shown clear benefits in the prevention of nausea and vomiting in chemotherapy-treated humans2. Cerenia tablets are also for the treatment for motion sickness in dogs aged 16 weeks or older, delivering claimed efficacy up to 93% without sedating the dog.
Kate Grocott, Product Manager for Cerenia, said: "Already successfully used in the treatment and prevention of vomiting and chemotherapy nausea in dogs, the new licence is a positive step forward for the prevention and early treatment of vomiting for puppies as young as eight weeks of age and cats from 16 weeks old. Being able to deploy Cerenia in these cases, will improve quality of life, and increases the likelihood of the animal voluntarily taking food and water thereby assisting in the recovery where there is underlying disease."
The new licence for treatment of cats with Cerenia is associated with the injectable form, while puppies may be treated with either an injection or tablets.
For further information, contact your Pfizer Animal Health account manager or call 0845 300 8034.
References
Pfizer's Vet Support+ has launched the Practice Management Academy, which offers online training in the key management disciplines required to run a successful veterinary business.
There are twelve courses which cover four key areas of management: financial operations, staff management, client relations and marketing. Participants can choose to study individual courses, a specific area of management, or enrol in the full Practice Management Academy.
The courses are four weeks in length and contribute up to ten hours of CPD learning through a mix of interactive activities, case studies, questions and a student learning forum.
Each course is also allocated a Pfizer Business Consultant to work as an online expert tutor, posing questions and stimulating forum discussion amongst the students.
Pfizer says that the significant cost saving e-learning represents over external CPD is making the Academy a popular choice for all members of the practice team, especially those who may be taking on new management responsibilities or those looking for a refresher. According to the company, one large vet group has already taken twenty places on each of the courses to improve the practice management skills across its extensive team.
Ned Flaxman, Director Business Innovation said: "Using an E-Learning platform is a well-trodden path, ideal for busy individuals wishing to improve or gain new practice management skills without leaving the surgery, or sofa. However, unlike some e-learning which can leave the participant feeling like they are gaining theoretical know-how only, and working in somewhat of a silo, our Academy offers an 'online campus'. This provides a flexible, convenient and supportive training environment for shared theory and practical learning with other colleagues from the veterinary profession under the guidance of e-tutors and experts."
For further details visit http://www.vetsupportplus.co.uk/
Pfizer has announced the results of research carried out as part of its Vet Support+ initiative, which shows that the three most important factors in engaging a veterinary team are: leadership, employee performance management and team effectiveness. Of the three, performance management is the most important.
The employee engagement survey was carried out to provide an insight to the veterinary market specifically. According to Pfizer more than 4,000 responses were received, providing insights from 749 practice owners, partners and practice managers and almost 3,500 individual veterinary practice employees. Analysis and modelling from an independent expert and the Vet Support+ team led to the identification of three drivers for an actively engaged team within a veterinary practice, and the creation of a national benchmark for employee engagement. Pfizer says Vet Support+ is committing to running the research on a regular basis so that employee engagement amongst all veterinary staff can be monitored on an ongoing basis.
Pfizer says that although recognised as the most important factor in generating good employee engagement, performance management was identified as an area of weakness in many practices. There were contradictory responses from management and staff regarding both formal appraisals and informal feedback taking place. In both cases, management tended to believe this was happening while staff disagreed. Of further frustration for staff was the management of poor performers, with 52% of staff stating that poor performers were not managed effectively.
Leadership is critical for any successful business, however the survey showed that while personal relationships between management and staff are good (79% of vets and 76% of staff agreed that the relationship between management and teams are generally good), there is a lack of trust between leadership and staff (80% of vets said they believe there is trust in the team, while only 62% of staff agreed).
Practice owners were more upbeat about team effectiveness: 76% said they believe the team was willing to put in more effort, while only 63% of staff agreed. There was another inconsistency regarding communication within the team, with only 49% of staff thinking that communication in practice is good versus 65% of practice owners.
Ned Flaxman, Director Business Innovation at Pfizer Animal Health said: "At face value this data makes for very interesting reading and the identification of the key drivers of engagement in practice is the practical benefit for practices to prioritise their focus of activity on staff management."
He added: "This research will enable us to work with practices to do their own employee engagement survey to be benchmarked against the national study. This will provide an evidence-based approach to identify the biggest gaps for improvement, and our Vet Support+ team can work with practices to deliver solutions for those challenges whether leadership, team effectiveness or performance management."
Practice owners and managers wishing to understand the data in more detail and measure levels of engagement within their own team against the evidence-based benchmarks the study provides should contact the Vet Support+ team at http://www.vetsupportplus.co.uk/
Key findings from the Employee Engagement Survey:
Pfizer is giving away a free equine weigh tape with every purchase of Equest & Equest Pramox (while stocks last), to help encourage accurate treatment against encysted small redworms this season.
According to the company, Equest & Equest Pramox are the only wormers in the UK that treat encysted small redworm in a single dose. Using a weigh tape to work out their horse's weight will help your clients avoid under dosing, which increases the risk of resistance development.
Pfizer says small redworms are the most common worms found in horses today. They can pose a very serious health risk to horses and it's important for owners to make sure that they are treated properly during the autumn or early winter.
Small redworms can grow up to 2.5cm in length and are thin and reddish in colour. Small redworm eggs are passed in the faeces and then hatch on pasture and continue to develop into more advanced larval stages before being ingested by the horse as it grazes. The larvae burrow deeply into the wall of the gut where they encyst and may account for up to 90% of the redworm burden in the horse1. Encysted small redworm will not show up in a Faecal Worm Egg Count - even if the horse has shown a negative or low count it could still be harbouring several million encysted small redworms2.
Encysted small redworms can remain dormant inside a horse for up to two years, but they usually 'wake-up' in late winter or early spring, developing and emerging from the gut wall all at the same time. In severe infestations mass emergence can lead to a disease syndrome known as 'larval cyathostominosis', causing diarrhoea and colic with up to a 50% mortality rate3. Young horses of less than six years of age can often be at higher risk of the disease3 but small redworm can cause life-threatening illness at any time of year and in any age of horse.
Ben Gaskell, Pfizer's veterinary adviser said: "Treating encysted small redworms successfully in the late autumn or early winter is important to avoid the risk of larval cyathostominosis. It's important to advise your customers to choose a product that is licensed to treat the worms they are targeting and that they give the correct dose, by weighing their horse beforehand, as this will help preserve the efficacy of the drug used."
Pfizer's Does your wormer measure up campaign is backed with point of sale materials and a media campaign. To receive a free weigh tape, valued at £7 your clients need to buy a tube of Equest or Equest Pramox, fill in an application form and send Pfizer the batch and expiry flap from the pack. Pfizer will then send them a FREE Weigh Tape while stocks last.
For further information contact your Pfizer Account Manager.
1. Bairden K. et al (2001) Veterinary Record 148, 138-1412. Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑2423. McWilliam H. et al (2010) International Journal for Parasitology 40, 265-275
Pfizer has repeated it's call for veterinary practice staff to take part in its Vet Support+ independent, industry-wide survey of employee engagement.
The survey gives practice team members, who are not partners or owners, the chance to have their say about their role and career and the future of the profession. Participants are asked to consider how they feel towards their practice and delve into issues on teamwork and communication, management techniques, personal development opportunities and working environment.
More than 3,000 vet practice staff have already completed the survey, a phenomenal early response which suggests practice employees are keen to have their voices heard. However, the closing date for the survey isn't till Friday 29th July, so if you haven't yet had a chance to do the survey, there is still time.
Pfizer Business Consultant, Vanessa Wilson, has more than 20 years experience helping businesses, teams and individuals achieve their goals. She is not surprised at the significant early response: "Questions on the level of employee engagement and satisfaction come up all the time in the work we do with practices. I'm not surprised that staff are using this opportunity to have their voice heard.
"Once completed, this survey will provide some very useful data and direction for the industry as a whole and I'd like to think it will identify opportunities for both individual career development and practice growth."
All members of staff employed within a practice who have not received a mailing and wish to participate are welcome to respond online. http://www.noesis-mi.com/surveys/employeesurvey/.
Pfizer says the findings, which are expected to be released in the autumn, will deliver a national and regional view of the current employee engagement landscape.
For further information about Vet Support+ Business Services from Pfizer visit www.vetsupportplus.co.uk.
Pfizer has released the results of its first Performance Index (formerly the Fort Dodge Index) which shows mildly improved trading conditions for the companion animal veterinary market in the first quarter of 2011.
Those aspects of veterinary business that showed an improvement in the first quarter of 2011 include: turnover growth (+0.8%, up from -0.1% in March 2010); client retention (+0.1%); the average number of visits per year (+ 0.17%); annual transaction value (+ 1.1%); average transaction value (+0.8% to £41.74); fee per product service (+0.2%) and products and services sold per visit (+0.6%).
Leveraged sales (typically pet-care products), which were down 2% (from 40% to 38%) in 2010, have increased 0.9% in the first quarter of 2011 to make up 39% of practice transactions.
Less positively and pointing to the need for veterinary practices to implement ongoing marketing initiatives, the number of new clients coming into practice is down (-0.4%) as is the number of active clients (-0.26%). Revenue from loyal clients (those that visit the practice for additional products and services, particularly vaccination and other preventative healthcare programmes) was static. Although flat growth is an improvement on previous reports, this is still a concern, as it is these clients who are the driver for revenue growth in many practices.
Pfizer Business Consultant, Simon Fowler said: "Although the figures are only very slightly improved this does mirror what we are seeing in practices that we visit. Practice turnover growth of 0.8%, while only small, is much better than any quarter in 2010. So we may be seeing the first green shoots of recovery, but there's still no room for complacency. Before we all breathe a collective sigh of relief, however, it should be remembered that as this is the first report for 2011 it is only an early picture, while a fuller story will be gleaned from the second report, which will show results from the first six months of the year.
"What is clear is the need for practices to market themselves in order to attract new clients, increase growth from active clients and increase client loyalty. VetSupport+ includes a range of marketing services to help practices in this respect. A practice has already achieved TV coverage via our Public Relations support service, while others are using PressRoom newsletter templates to keep potential and existing clients up to speed with the practice's news."
Further information about Pfizer's VetSupport+ service is available at www.vetsupportplus.co.uk.
According to a survey carried out by Pfizer, veterinary surgeons are generally upbeat about the business prospects for their practice this year, despite predicting a harsh economic environment for the industry as a whole in 2011.
The Pulse Survey of more than 400 practice owners and their senior management teams, which presents a snapshot of market sentiment, revealed that predictions for the veterinary market in general remained as gloomy as 2010. Over half (52%) of respondents believed that conditions for the industry would get more challenging.
However, the response from owners about their own practice's performance was more bullish with a third (34%) believing their prospects will improve.
Pfizer Business Consultant, James White, said: "Practices are right to remain cautiously optimistic about 2011 if we accept it's going to be a challenging year. Some practices came slightly unstuck in 2010 as a result of the knock-on effects of the economic downturn on pet owners' pockets. However, by implementing the correct strategies now there are still opportunities for growth. Client loyalty is the buzz word and should remain a key component of any practice strategy being implemented in the coming months."
Pfizer launched the Pulse survey in Autumn 2010 to deliver up to date analysis on a range of issues that senior management teams at practice level are witnessing. According to the company, the survey is attracting a growing volume of respondents. All participants receive a summary report of the Pulse Survey findings.
Pfizer's team of Business Consultants is working with practices throughout the country to pinpoint their individual business challenges, offer solutions through the company's Vet Support+ service and work with the practices to drive growth. For further information visit http://www.vetsupportplus.co.uk/.
Pfizer, manufacturer of the wormer Strongid™-P has launched a new promotional campaign. Love your horse is based on simple, straightforward and unbiased educational messages to help ensure the optimum health and wellbeing of horses and ponies in the UK.
Pfizer's veterinary adviser Ben Gaskell said: “Simplistically, the three key tools for the horse owner to understand are diagnostics, worming and pasture management. If these tools are used in combination with specialist advice, then the horse owner will be able to provide a sustainable, reliable and cost-effective worm control strategy for their horse.”
At the core of the campaign is a new range of four highly informative and uncomplicated leaflets directed at every type of horse owner: Do you need to worm; Choosing and using the right wormer; Managing your pasture and Worming and Your new horse.
“Each leaflet has been designed to work as a stand-alone piece or can be presented as a smart, matching series of four,” said Helen Shirley, brand manager for Strongid™-P. “The leaflets can be displayed in-store in a distinctive counter-top leaflet dispenser and are supported by eye-catching point of sale materials including posters and balloons." The new campaign packs will be rolled out to all stockists from early June, supported by a dramatic new Love your horse advertisement in national equestrian trade and consumer titles.
The campaign will build up momentum over the summer months and into autumn’s double dosing time with a series of authoritative, no-nonsense features and news stories from Strongid™-P’s veterinary advisor Ben Gaskell.
For further information please email: Strongid-P@pfizer.com
Two recently published studies have demonstrated that the canine anti-emetic Cerenia® (maropitant - Pfizer) which was launched last year also relieves car sickness in dogs.
In a pilot study, 17 dogs were given either Cerenia or placebo one hour before being taken on a car journey. After a washout period of 10-14 days, each dog was crossed over to the other treatment and once again taken on a journey to assess travel sickness. The results showed that likelihood of vomiting was reduced by 70% when the dogs were given Cerenia compared to placebo – but due to the small number of dogs enrolled the results did not reach statistical significance.
The same research group also carried out a large, multicentre, blinded and placebo controlled study of Cerenia in preventing vomiting in 213 dogs known to be prone to travel sickness. They were given a single oral dose of Cerenia or placebo one hour before a car journey. The results showed that Cerenia was associated with a reduction in vomiting of 79% compared to placebo (p<0.0001).
The dosage of Cerenia used in both studies was 8mg/kg dose for the prevention of motion sickness–higher than the 2mg/kg dose that is routinely used to treat general emesis, administered at least one hour before the journey. According to the researchers’ report in the Veterinary Record, the need for a higher dose is linked to the specific neural (central) pathway of emetic stimulation that is involved in motion sickness. Cerenia acts primarily at NK1 receptors in the emetic centre and thus has the ability to block vomiting due to vestibular stimuli.
According to Pfizer, a single oral dose lasts for at least 12 hours, so pets can be dosed the night before an early start. For motion sickness prevention, Cerenia is licensed for up to 2 days’ consecutive use, so owners can use it for a return journey the next day if need be.
Pfizer also says that market research suggests almost one in five dogs suffers from travel sickness, which is not only inconvenient but does also stop some owners from travelling with their pet. In the past, owners have had to rely on OTC (over the counter) remedies or medicines developed for use in humans to prevent travel sickness. Many of these are ineffective or have unwanted effects such as sedation or extrapyramidial effects in dogs. Cerenia is the first anti-emetic to be developed specifically for use in dogs and was launched in April 2007– higher dose tablets aimed specifically for the prevention of travel sickness are expected to be made available early this year.